| Prediction for progression risk in patients with COVID-19 pneumonia: the CALL score D Ji, D Zhang, J Xu, Z Chen, T Yang, P Zhao, G Chen, G Cheng, Y Wang, ... Clinical Infectious Diseases 71 (6), 1393-1399, 2020 | 727 | 2020 |
| Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study D Ji, E Qin, J Xu, D Zhang, G Cheng, Y Wang, G Lau Journal of hepatology 73 (2), 451-453, 2020 | 547 | 2020 |
| Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents C Wang, D Ji, J Chen, Q Shao, B Li, J Liu, V Wu, A Wong, Y Wang, ... Clinical Gastroenterology and Hepatology 15 (1), 132-136, 2017 | 241 | 2017 |
| High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects C Chen, BMY Cheung, AWK Tso, Y Wang, LSC Law, KL Ong, NMS Wat, ... Diabetes care 34 (9), 2113-2115, 2011 | 215 | 2011 |
| Increased neutrophil elastase and proteinase 3 and augmented NETosis are closely associated with β-cell autoimmunity in patients with type 1 diabetes Y Wang, Y Xiao, L Zhong, D Ye, J Zhang, Y Tu, SR Bornstein, Z Zhou, ... Diabetes 63 (12), 4239-4248, 2014 | 198 | 2014 |
| Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta‐analysis G Chen, C Wang, J Chen, D Ji, Y Wang, V Wu, J Karlberg, G Lau Hepatology 66 (1), 13-26, 2017 | 184 | 2017 |
| Fibroblast growth factor 21 protects against acetaminophen‐induced hepatotoxicity by potentiating peroxisome proliferator‐activated receptor coactivator protein‐1α‐mediated … D Ye, Y Wang, H Li, W Jia, K Man, CM Lo, Y Wang, KSL Lam, A Xu Hepatology 60 (3), 977-989, 2014 | 171 | 2014 |
| Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2 D Ye, K Yang, S Zang, Z Lin, HT Chau, Y Wang, J Zhang, J Shi, A Xu, ... Journal of Hepatology 65 (5), 988-997, 2016 | 168 | 2016 |
| Organization of the Caenorhabditis elegans small non-coding transcriptome: genomic features, biogenesis, and expression W Deng, X Zhu, G Skogerbø, Y Zhao, Z Fu, Y Wang, H He, L Cai, H Sun, ... Genome research 16 (1), 20-29, 2006 | 155 | 2006 |
| Adropin is a brain membrane-bound protein regulating physical activity via the NB-3/Notch signaling pathway in mice CM Wong, Y Wang, JTH Lee, Z Huang, D Wu, A Xu, KSL Lam Journal of Biological Chemistry 289 (37), 25976-25986, 2014 | 135 | 2014 |
| Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study G Lau, Y Benhamou, G Chen, J Li, Q Shao, D Ji, F Li, B Li, J Liu, J Hou, ... The lancet Gastroenterology & hepatology 1 (2), 97-104, 2016 | 99 | 2016 |
| Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation H Liu, XI He, Y Wang, S Zhou, D Zhang, J Zhu, Q He, Z Zhu, G Li, L Sun, ... Hepatology international 14, 432-436, 2020 | 72 | 2020 |
| Clinical characteristics predicting progression of COVID-19 D Ji, D Zhang, Z Chen, Z Xu, P Zhao, M Zhang, L Zhang, G Cheng, ... | 67 | 2020 |
| Implication of non-alcoholic fatty liver diseases (NAFLD) in patients with COVID-19: a preliminary analysis D Ji, E Qin, J Xu, D Zhang, G Cheng, Y Wang, G Lau J Hepatol 73 (2), 451-453, 2020 | 66 | 2020 |
| Effect of COVID-19 on patients with compensated chronic liver diseases D Ji, D Zhang, T Yang, J Mu, P Zhao, J Xu, C Li, G Cheng, Y Wang, ... Hepatology international 14, 701-710, 2020 | 58 | 2020 |
| Profiling Caenorhabditis elegans non-coding RNA expression with a combined microarray H He, L Cai, G Skogerbø, W Deng, T Liu, X Zhu, Y Wang, D Jia, Z Zhang, ... Nucleic acids research 34 (10), 2976-2983, 2006 | 48 | 2006 |
| Reply to:‘No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease’ D Ji, J Xu, E Qin, D Zhang, G Cheng, Y Wang, G Lau Journal of hepatology 73 (3), 718-719, 2020 | 11 | 2020 |
Aimin XuDepartment of Medicine, Department of Pharmacology and Pharmacy, the University of Hong KongVerified email at hku.hk
